MISSISSAUGA, Ontario, September 26, 2016 – Microbix Biosystems Inc. (MBX:TSX), the world’s largest producer of viral disease antigens used in diagnostic tests, will bring to MEDICA 2016 three new weapons, which diagnostic test developers and researchers can now wield in the battle against dengue fever, a mosquito-borne tropical disease that’s been a global problem since World War II.
MEDICA takes place again this year in Düsseldorf, Germany, November 14-17. With more than 5,000 exhibitors expected from over 60 countries this year. MEDICA is the world’s largest annual medical trade fair and considered the world stage for launching medical innovations.
“We’ve been wanting to launch our new Microbix dengue antigens for a couple of years now,” says Phil Casselli, the company’s Senior Vice-President Sales & Business Development. “Our DEN (dengue) 2 antigen has been a leading product for immunodiagnostic assay manufacturers globally for years now but dengue fever has not just one, but four different serotypes. So at MEDICA this year we will be showcasing our new DEN 1, 3, and 4 antigens.”
Casselli explains further that this complete range of dengue antigens including NS1 protein can, among its other benefits, improve the sensitivity of dengue assays generally and make for better assays detecting antibodies in serum specifically. The Company will also be creating positive controls for molecular tests as an adjunct to its line of dengue products. As well, the new antigens will aid researchers looking for serotype specific antibody generation in animal studies.
In addition to the new dengue antigens, Microbix at MEDICA this year will also feature its latest response to the growth of molecular testing platforms.
“Microbix has been providing quality control samples to CAP (College of American Pathologists) approved proficiency program suppliers since 2009, and now with molecular testing becoming more commonplace, we have enhanced our antigen products with respect to cross-reactivity to ensure molecular assay compatibility. Our positive and negative samples can be used as simulated patient samples” says Casselli.
With similar product improvements, adds Casselli, Microbix can now provide single or multiple pathogens. The company’s molecular samples also include human DNA needed to mimic genuine patient samples.
Before MEDICA opens this fall, Microbix will be making a further announcement about other initiatives including RED Controls™ for unassayed control reagents used in in vitro molecular diagnostic assays.
Microbix Biosystems Inc. specializes in the research and development of biological solutions, including products for human health applications, namely in the vaccine, therapeutic, and diagnostic markets, as well as animal reproductive markets worldwide. The Company manufactures and distributes a wide range of infectious disease antigens to a worldwide customer base. The Company’s pipeline of innovative technologies and products includes LumiSort™ semen sexing technology for the livestock industries and Kinlytic®, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots. Established in 1988, Microbix is a publicly traded company, listed on the Toronto Stock Exchange, and headquartered in Mississauga, Ontario.
To learn more about Microbix, we invite you to visit us during MEDICA 2016 at the Ontario/Canada Pavilion, Hall 3, Booth H14.
You can also locate us in “Companies & Products" on the medica-tradefair.com portal.
Exhibitor Data Sheet